8-K: Omada Health Q3 2025: Revenue Up 49%, Net Loss Shrinks

Omada Health reports strong third-quarter 2025 results with significant revenue growth, reduced net loss, positive Adjusted EBITDA, and a new GLP-1 offering.

Summary

• Total members reached 831,000, marking a 53% increase compared to the third quarter of 2024.
• Revenue for the third quarter was $68 million, a 49% increase compared to the third quarter of 2024.
• Net loss significantly decreased to $3 million, compared to a net loss of $9 million in the third quarter of 2024.
• Achieved positive Adjusted EBITDA of $2 million, a substantial improvement from an Adjusted EBITDA loss of $5 million in the third quarter of 2024.
• Gross margin improved to 66% (GAAP) and 68% (Non-GAAP) for the quarter.
• Announced plans to launch a new prescribing offering combining evidence-based behavior change with medication management for anti-obesity medications (AOMs), including GLP-1s.
• Published its 30th peer-reviewed manuscript, demonstrating significant cost savings from Omada's Joint & Muscle Health program.
• Released data showing members largely maintained weight one year after discontinuing GLP-1 therapy, challenging widespread assumptions.
• Launched Omada Meal Map, an AI-powered nutrition experience focusing on nutrient quality.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with significant revenue and member growth, a substantial reduction in net loss, and the achievement of positive Adjusted EBITDA. The raised full-year guidance and strategic initiatives in GLP-1 and AI further contribute to a highly positive outlook.

Positives

• Revenue grew by 49% year-over-year to $68 million in Q3 2025.
• Total members increased by 53% year-over-year to 831,000.
• Net loss was significantly reduced to $3 million in Q3 2025 from $9 million in Q3 2024.
• Achieved positive Adjusted EBITDA of $2 million in Q3 2025, a turnaround from a $5 million loss in Q3 2024.
• GAAP gross margin improved to 66% in Q3 2025 from 63% in Q3 2024.
• Non-GAAP gross margin improved to 68% in Q3 2025 from 65% in Q3 2024.
• Cash and cash equivalents stood at a strong $199 million as of September 30, 2025.
• Raised full-year 2025 revenue guidance to a range of $251.5 million to $254.5 million, up from the prior range of $235 million to $241 million.
• Raised full-year 2025 Adjusted EBITDA guidance to a range of a $2 million loss to breakeven, up from the prior range of a $9 million to $5 million loss.
• Announced a new GLP-1 prescribing offering, expanding its service portfolio.
• Published its 30th peer-reviewed manuscript, validating the clinical and economic effectiveness of its programs.
• Released data demonstrating sustained weight maintenance post-GLP-1 therapy, providing a competitive differentiator.
• Launched Omada Meal Map, an AI-powered nutrition tool, enhancing its AI capabilities.

Negatives

• The company still reported a net loss of $3 million for the quarter, despite significant improvement.
• The full-year Adjusted EBITDA guidance still includes a potential loss of up to $2 million.

Risks

• Limited operating history and ability to manage growth effectively.
• History of net losses and ability to achieve or maintain profitability.
• The ability of programs to achieve and maintain market acceptance.
• Changes in the healthcare industry and competition.
• The growth and success of customers and channel partners.
• The number of individuals covered by programs and the number of programs covered by customers.
• The level of member engagement in programs.
• Ability to maintain and grow customer and channel partner relationships.
• Concentration of a substantial portion of sales among a limited number of customers and channel partners.
• Ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners.
• Ability to increase the size of the organization.
• Dependence on a limited number of third-party suppliers.
• The impact of seasonality on financial results.
• Ability to achieve widespread brand awareness and the impact of any negative media coverage.
• Ability to develop and release new programs and services.
• Cybersecurity threats.
• Dependence on the interoperability of programs and connected devices with third-party devices, operating systems and applications.
• Changes in laws or regulations or the implementation of existing laws and regulations.
• Compliance with privacy and security laws and regulations.
• Compliance with healthcare regulatory laws by Omada and its affiliated professional entities.
• Any modification in U.S. Food and Drug Administration enforcement policies.
• Dependence on relationships with affiliated professional entities.

Future Outlook

Omada expects full-year 2025 revenue in the range of $251.5 million to $254.5 million, an increase from the prior range of $235 million to $241 million. Adjusted EBITDA for the full year is now expected in a range of a $2 million loss to breakeven, improved from the prior range of a $9 million to $5 million loss. The company also plans to launch a new GLP-1 prescribing offering and continue advancing its AI capabilities.

Management Comments

• "Our third quarter results demonstrate the strength of Omada’s multi-product platform in a moment of intense national focus on obesity-related chronic disease."
• "We also took important steps to deepen our innovation in GLP-1 care options and advance our AI capabilities, both aimed at delivering meaningful and sustainable outcomes for our members and cost savings for customers."

Industry Context

The announcement highlights Omada's strong position in the virtual healthcare market, particularly in addressing cardiometabolic conditions and musculoskeletal issues. The focus on GLP-1 care options and AI capabilities aligns with broader industry trends towards personalized, technology-driven health solutions and the increasing demand for obesity management. The data on weight maintenance post-GLP-1 therapy challenges existing market assumptions, potentially positioning Omada as a leader in long-term outcomes for anti-obesity medications.

Comparison to Industry Standards

• Omada's 49% revenue growth and 53% member growth are strong indicators in the virtual healthcare sector, which is generally experiencing robust expansion, often outpacing traditional healthcare segments.
• Achieving positive Adjusted EBITDA of $2 million marks a significant milestone, demonstrating progress towards profitability, which is a key challenge for many growth-stage digital health companies, such as Teladoc Health or Livongo (prior to acquisition), which often prioritize growth over immediate profitability.
• The publication of 30 peer-reviewed manuscripts and data on sustained weight loss post-GLP-1 therapy provides strong clinical differentiation, setting Omada apart from competitors that may lack such extensive evidence-based validation for their programs, like some newer digital health startups in the weight management space.
• The launch of AI-powered tools like Omada Meal Map and OmadaSpark positions Omada competitively against other digital health platforms leveraging AI for personalized care, such as Noom or WeightWatchers, by focusing on nutrient quality over simple calorie counting.

Related Party Transactions

• Accounts receivable, net includes $29.3 million from a related party as of September 30, 2025, compared to $13.2 million as of December 31, 2024.
• Accrued expenses and other current liabilities include $5.2 million from a related party as of September 30, 2025, compared to $2.2 million as of December 31, 2024.
• Deferred revenue includes $20.3 million from a related party as of September 30, 2025, compared to $13.2 million as of December 31, 2024.
• Services revenue includes $41.8 million from a related party for the three months ended September 30, 2025, and $108.2 million for the nine months ended September 30, 2025.
• Hardware revenue includes $3.0 million from a related party for the three months ended September 30, 2025, and $9.0 million for the nine months ended September 30, 2025.
• Cost of services revenue includes $1.4 million from a related party for the three months ended September 30, 2025, and $3.8 million for the nine months ended September 30, 2025.
• Research and development expense includes $0.6 million from a related party for the three months ended September 30, 2025, and $1.6 million for the nine months ended September 30, 2025.
• Sales and marketing expense includes $7.1 million from a related party for the three months ended September 30, 2025, and $19.3 million for the nine months ended September 30, 2025.
• General and administrative expense includes $0.4 million from a related party for the three months ended September 30, 2025, and $1.1 million for the nine months ended September 30, 2025.
• Provision for credit losses includes changes in related party balances of $0.5 million for the nine months ended September 30, 2025.
• Changes in accounts receivable include related party balances of $15.6 million for the nine months ended September 30, 2025.
• Changes in accrued expenses and other current liabilities include related party balances of $3.0 million for the nine months ended September 30, 2025.
• Changes in deferred revenue include related party balances of $7.1 million for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders are likely to view the strong financial performance, including significant revenue growth, reduced net loss, and positive Adjusted EBITDA, along with raised full-year guidance, favorably, potentially leading to increased shareholder value.
• Customers (health plans, health systems, and employers) will benefit from the launch of new GLP-1 prescribing offerings, evidence of cost savings from programs, and data challenging post-medication weight gain assumptions, enhancing Omada's value proposition and potentially leading to increased adoption and retention.
• Members will benefit from new offerings like the GLP-1 prescribing program and Omada Meal Map, combined with evidence-based care and AI-powered technology, which aim to improve health outcomes and provide more personalized care.
• Employees may experience increased job stability and potential expansion opportunities due to the company's continued growth and innovation.

Next Steps

• Launch of the new GLP-1 prescribing offering.
• Continued innovation in GLP-1 care options.
• Further advancement of AI capabilities, including the Omada Meal Map.
• Host a conference call on November 6, 2025, at 1:30 p.m. PT/4:30 p.m. ET to discuss third-quarter results.

Key Dates

Recommendation

Omada Health demonstrated robust financial performance in Q3 2025, significantly growing revenue by 49% and achieving its first quarter of positive Adjusted EBITDA. The substantial reduction in net loss and the upward revision of full-year guidance for both revenue and Adjusted EBITDA signal strong operational momentum and a clear path towards sustained profitability. Strategic initiatives, particularly the new GLP-1 prescribing offering and advancements in AI, position the company well within a high-growth segment of the healthcare market. The clinical differentiation, evidenced by peer-reviewed publications and data challenging common assumptions about GLP-1 therapy, further strengthens its competitive advantage. These factors, combined with a healthy cash position, suggest a compelling investment opportunity.

Keywords

Omada Health, virtual healthcare, GLP-1, anti-obesity medications, chronic disease management, diabetes, hypertension, prediabetes, obesity, musculoskeletal, AI, digital health, Q3 2025 earnings, financial results, telehealth